(Albany, USA) DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market.
Request for a Free Sample Report @ Rheumatoid Arthritis Market Forecast
Some facts of the Rheumatoid Arthritis Market Report are:
- According to DelveInsight, Rheumatoid Arthritis market size is expected to grow at a decent CAGR by 2032.
- As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021.
- According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4.7 million in 2021.
- Leading Rheumatoid Arthritis companies working in the market are Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others.
- Key Rheumatoid Arthritis Therapies expected to launch in the market are Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/ MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others.
- On Jan 2024, Rise Therapeutics announced A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis.
- On April 2024, IGM Biosciences announced a Phase 1b, randomized, placebo-controlled, multicentre study to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of imvotamab in adult participants with active RA who are refractory or intolerant to 2 previous biologic disease-modifying anti-rheumatic drugs (bDMARD) or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARD) therapies. Approximately 24 participants will be sequentially assigned to different dose escalation cohorts.
- On March 2024, Sanofi announced a Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis Overview
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints, causing inflammation, pain, swelling, and stiffness. It can also affect other organs and systems in the body. Rheumatoid arthritis occurs when the immune system mistakenly attacks the synovium, the lining of the membranes that surround the joints, leading to inflammation and damage to cartilage and bone.
The exact cause of Rheumatoid arthritis is unknown, but genetic, environmental, and hormonal factors are believed to play a role. It typically affects women more often than men and can develop at any age, although it most commonly starts between the ages of 30 and 60.
Treatment for Rheumatoid arthritis aims to control symptoms, prevent joint damage, and improve quality of life. This often involves a combination of medications (such as disease-modifying anti rheumatic drugs and biologic agents), lifestyle changes, physical therapy, and sometimes surgery. Early diagnosis and intervention are key to managing Rheumatoid arthritis effectively and reducing long-term complications.
Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Rheumatoid Arthritis Market
The Rheumatoid Arthritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Rheumatoid Arthritis market trends by analyzing the impact of current Rheumatoid Arthritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Rheumatoid Arthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Rheumatoid Arthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.
According to DelveInsight, the Rheumatoid Arthritis market in 7MM is expected to witness a major change in the study period 2019-2032.
Rheumatoid Arthritis Epidemiology
The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Rheumatoid Arthritis Epidemiology @ Rheumatoid Arthritis Market Dynamics
Rheumatoid Arthritis Drugs Uptake
This section focuses on the uptake rate of the potential Rheumatoid Arthritis drugs recently launched in the Rheumatoid Arthritis market or expected to be launched in 2019-2032. The analysis covers the Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Rheumatoid Arthritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Rheumatoid Arthritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Rheumatoid Arthritis Pipeline Development Activities
The Rheumatoid Arthritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Rheumatoid Arthritis key players involved in developing targeted therapeutics.
- Artlegia (Olokizumab): R-Pharm
- TS-152 (Ozoralizumab): Taisho Pharmaceuticals
- Otilimab (GSK3196165/MOR103): GlaxoSmithKline
- ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics
- Branebrutinib: Bristol Myers Squibb
- LY3462817: Eli Lilly and Company
- TAS5315: Taiho Pharmaceutical
- Rabeximod (Rob 803): Cyxone
- GS-5718: Gilead Sciences
- KPL-404: Kiniksa Pharmaceuticals
- MBS2320: Istesso
- AMT-101: Applied Molecular Transport
- Dazodalibep (HZN-4920): Horizon Therapeutics
- Cevidoplenib (SKI-O-703): Genosco/Oscotec
- HB-AdMSCs: Hope Biosciences
- ABX464: Abivax
- MPC-300-IV: Mesoblast
- PF-06650833: Pfizer
- JTE 051: Akros Pharma/Japan Tobacco
- Dekavil (F8IL10): Pfizer/Philogen
- ABBV-154: AbbVie
- PF-06651600 (Ritlecitinib): Pfizer
- AP1189: SynAct Pharma
Request for a sample report to understand more about the Rheumatoid Arthritis pipeline development activities @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Rheumatoid Arthritis Therapeutics Assessment
Major key companies are working proactively in the Rheumatoid Arthritis Therapeutics market to develop novel therapies which will drive the Rheumatoid Arthritis treatment markets in the upcoming years are R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly and Company, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco/Oscotec, Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, Pfizer, SynAct Pharma, Incyte Corporation, Immunex, UCB, Astellas Pharma, Roche, Galapagos, Gilead Sciences, Swedish Orphan Biovitrium (SOBI), and others.
Learn more about the emerging Rheumatoid Arthritis therapies & key companies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Rheumatoid Arthritis Report Key Insights
1. Rheumatoid Arthritis Patient Population
2. Rheumatoid Arthritis Market Size and Trends
3. Key Cross Competition in the Rheumatoid Arthritis Market
4. Rheumatoid Arthritis Market Dynamics (Key Drivers and Barriers)
5. Rheumatoid Arthritis Market Opportunities
6. Rheumatoid Arthritis Therapeutic Approaches
7. Rheumatoid Arthritis Pipeline Analysis
8. Rheumatoid Arthritis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Rheumatoid Arthritis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Rheumatoid Arthritis Competitive Intelligence Analysis
4. Rheumatoid Arthritis Market Overview at a Glance
5. Rheumatoid Arthritis Disease Background and Overview
6. Rheumatoid Arthritis Patient Journey
7. Rheumatoid Arthritis Epidemiology and Patient Population
8. Rheumatoid Arthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Rheumatoid Arthritis Unmet Needs
10. Key Endpoints of Rheumatoid Arthritis Treatment
11. Rheumatoid Arthritis Marketed Products
12. Rheumatoid Arthritis Emerging Therapies
13. Rheumatoid Arthritis Seven Major Market Analysis
14. Attribute Analysis
15. Rheumatoid Arthritis Market Outlook (7 major markets)
16. Rheumatoid Arthritis Access and Reimbursement Overview
17. KOL Views on the Rheumatoid Arthritis Market
18. Rheumatoid Arthritis Market Drivers
19. Rheumatoid Arthritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting